在聚氨上氧化碳甲基纤维素的表面固定,用于持续的药物输送
Manali Somani1, Chetna Verma1, Flavius Phrangsngi Nonglang2
1Department of Textile and Fibre Engineering, Indian Institute of Technology, New Delhi, 110016, India.
Macromolecular bioscience
|August 12, 2024
概括
这项研究开发了一种抗菌的聚氨表面,通过使含有酸的氧甲基纤维素固定不动. 改性聚氨 (PU-ON) 显示出优异的抗感染性和生物医疗用途的生物相容性.
科学领域:
- 生物材料科学 生物材料科学
- 聚合物化学 聚合物化学
- 表面修改 表面修改
背景情况:
- 聚氨 (PU) 具有可调节的特性,非常适合生物医学应用.
- 表面修饰对于提高生物材料的功能至关重要.
- 开发抗菌表面对于预防医疗器械相关感染至关重要.
研究的目的:
- 通过共价性固定氧甲基纤维素 (CMC) 和酸黄 (NF) 来创建抗菌聚氨表面.
- 通过希夫基化学研究氧化CMC (OCMC) 到氨化PU (PU-A) 的固定.
- 评估修改PU表面 (PU-ON) 的抗菌有效性和生物相容性.
主要方法:
- 通过氨解来改变PU的表面.
- 用希夫基化学方法将氧化CMC对PU-A进行共价固定.
- 使用SEM,接触角度,XPS和EDX分析进行表征.
- 在体外抗菌测试和体内感染耐药性评估.
主要成果:
- 在PU-A上OCMC的成功固定被SEM,接触角度和XPS证实.
- 通过EDX.验证的酸黄 (NF) 融入OCMC凝和PU表面 (PU-ON).
- PU-ON 证明了与度相关的细菌静止和杀菌作用,对抗格拉姆阳性和格拉姆阴性细菌.
- 观察到NF的持续释放和优异的体内感染耐药性.
结论:
- 开发的PU-ON表面有效地固定NF,提供持续的抗菌活性.
- 修改后的PU材料具有显著的抗感染性和生物相容性.
- 这种方法为制造用于医疗应用的先进抗菌生物材料提供了一个有希望的策略.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...